News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Biopharma Trends in 2024 and Beyond

January 17, 2024
By Gaurav Kapoor
Commentary
Article

Generative artificial intelligence, key new product launches, and the evolution of the go-to-market model are among key trends to watch in the year ahead.

Image credit: Alexander Limbach | stock.adobe.com

Image credit: Alexander Limbach | stock.adobe.com

The Inflation Reduction Act (IRA), mergers and acquisitions, obesity-control drugs, and artificial intelligence (AI) dominated the pharma industry’s headlines in 2023. And although they will continue to be a part of industry conversations, there are five major trends poised to occupy centerstage in 2024 and beyond:

1. Pharma companies prune portfolio to maximize profitability

2023 saw a few pharma companies spin off their generics businesses into separate companies to focus on their innovative products pipeline. As the IRA puts pressure on pricing, biopharma companies will continue to optimize their portfolios and business strategy in 2024. We anticipate them to focus a lot more on upcoming launches. It is critical they get these launches right. They will make tough decisions on the right go-to-market (GTM) models for their launch products versus those in mature stages and those about to lose exclusivity (LOE). Focus and partnerships will be key to their strategy in 2024 and beyond.

2. Launches make-or-break companies

With 25-275 launches over 2023-27 and about $108 billion in new drug spending in the United States on them, launch success will be critical to company success in 2024. Our study with commercial leaders with deep experience in product launches found five factors are vital to commercial success: payer activation and reimbursement, intelligent and early regulatory engagement, wide adoption by target HCPs, much better field force effectiveness and efficiency, and excellent patient engagement and adoption. Breakthrough companies will bring superior people, process and capabilities to bear across these factors to make launches successful.

3. Generative artificial intelligence (GenAI) gets to work

While 2023 introduced pharma leaders to GenAI’s possibilities, 2024 is they year they will truly put GenAI to work. Sanofi already announced its responsible AI principles and many others will likely follow suit. Pharma companies will prioritize a few high impact use cases from the many possible, identify the right data sets to enable GenAI, contextualize AI for medical use cases, build required governance models, and validate ROI for enterprise-wide adoption. From clinical to medical to commercial, GenAI promises to drive effectiveness and efficiency across use cases, but domain knowledge and a practitioner perspective would be key to derive value from GenAI.

4. Pharma companies will take steps towards a new GTM model

Pharma GTM models are still stuck in a pre-COVID world with a digital veneer on it. We swung the pendulum from fully-rep-led to fully-digital launches and missed the bus on enabling the field force with digital channels and experiences. The future is hybrid. Pharma companies will evolve their GTM models in 2024. Companies that seamlessly integrate their agency of record (AOR), contract sales organization (CSO) and direct-to-consumer (DTC) partners together will forge ahead of others. This truly omnichannel experience is vital to engaging HCPs and patients and ensure success in the future.

5. GBS partners with service providers to drive value and innovation

An Everest Group study across industries found 48% of enterprise respondents expecting to shift to a shared services or global business services (GBS) sourcing model. Biopharma has been slow to adopt this model. However, as GBS transitions from capacity to capability centers and enterprises’ expectations from GBS evolves from cost productivity to augmenting technology capabilities and strategic process re-engineering, pharma GBS centers will increasingly partner with specialist service providers to augment and elevate inhouse capabilities.

As the pharma industry rebalanced its priorities post-COVID in 2023, 2024 promises to be the year when it builds on its resilience and accelerates the development of core capabilities necessary to drive sustainable, profitable growth in the future.

About the Author

Gaurav Kapoor, EVP, Indegene.

Recent Videos
Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Cell and Gene Therapy Check-in 2024

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
January 18th 2024
Podcast

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.


Earned Media and ASCO: Provide Context Beyond the Data

Earned Media and ASCO: Provide Context Beyond the Data

Michael Christel
May 13th 2025
Article

The latest Q&A installment in Pharm Exec's earned media series details key strategies for leveraging breaking news at industry trade shows, including the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.


Industry Outlook 2022

Industry Outlook 2022

Elaine Quilici;Miranda Schmalfuhs
January 20th 2022
Podcast

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.


Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Thermo Fisher to Invest $2 Billion in US Biotech Manufacturing, R&D

Don Tracy, Associate Editor
April 28th 2025
Article

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.


Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation

Don Tracy, Associate Editor
April 22nd 2025
Article

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.